September 20th 2024
The approval of amivantamab plus carboplatin and pemetrexed is supported by data from the phase 3 MARIPOSA-2 trial.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Basing Lung Cancer Screening Guidelines on Individual Risk Could Be Effective
May 27th 2016An individualized, risk-based approach to screening current and former smokers for the early detection of lung cancer would dramatically expand the population that could benefit from the preventive strategy.
Read More
CHMP Recommends Approval for Bevacizumab/Erlotinib Regimen for NSCLC
May 6th 2016The Committee for Medicinal Products for Human Use has recommended the first-line approval of bevacizumab (Avastin) in combination with erlotinib (Tarceva) for patients with advanced or metastatic EGFR-mutant non-small cell lung cancer.
Read More
Osimertinib Shows Promise in EGFR T790M-Mutant NSCLC Trials
May 5th 2016Mature data from both the phase I and phase II portions of the AURA study paints a bright, hopeful future for the use of third-generation TKI osimertinib (AZD9291) in patients with EGFR T790M-mutant non-small cell lung cancer.
Read More
FDA Committee Denies Rociletinib Accelerated Approval in Lung Cancer
April 13th 2016The FDA's Oncologic Drugs Advisory Committee (ODAC) voted 12-1 against the accelerated approval of rociletinib for patients with metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC) who have previously received an EGFR-targeted therapy.
Read More
Possible Treatment on Horizon for Advanced KRAS-Mutant NSCLC
April 5th 2016Promising early phase clinical trials have led to the initiation of the phase III JUNIPER trial, which is assessing abemaciclib (LY2835219) for patients with previously treated KRAS-mutant lung cancer, a traditionally hard to treat genetic subtype.
Read More
Dr. Thomas Stinchcombe on Targeted Therapies in Squamous Cell Lung Cancer
April 4th 2016Thomas Stinchcombe, MD, discusses the complicated nature of squamous cell lung cancer. Stinchcombe says that there has been a recent boom in targeted therapies for non-squamous cell lung cancer, though not as much research in squamous cell lung cancer due to its multitude of mutations.
Watch
Anti-PD-1 Agents Now Second-Line Treatment of Choice for NSCLC
April 1st 2016In an interview with Targeted Oncology, Sarah Goldberg, MD, MPH, assistant professor of Medicine and Medical Oncology, Yale Cancer Center, discussed the efficacy of immunotherapies, PD-L1 as a biomarker, and how these therapies will continue to alter the treatment of patients with lung cancer.
Read More
Dr. Christina Baik on Alectinib in Patients With ALK-Lung Cancer
April 1st 2016Christina Baik, MD, MPH, assistant professor, Seattle Cancer Care Alliance, Thoracic/Head and Neck, Department of Medicine, Division of Medical Oncology, University of Washington, discusses the efficacy of alectinib after first-line crizotinib in patients with ALK-positive lung cancer. Baik says alectinib generally works for about 8 months and is easy to take for patients.
Watch
PD-L1/CTLA-4 Blockade and the Future of Immunotherapies in Lung Cancer
March 31st 2016The combination of the PD-L1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab, showed antitumor activity in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), irrespective of PD-L1 status, according to a recent phase Ib study published in The Lancet Oncology.
Read More
Dr. Edward Kim on Indicating Patient Populations With Biomarkers in NSCLC
March 29th 2016Edward Kim, MD, chair of the department of Solid Tumor Oncology, Levine Cancer Institute, discusses the further work that needs to be done when indicating patient populations with certain biomarkers in non-small cell lung cancer (NSCLC).
Watch